Reply: CNS prophylaxis in diff use large B-cell lymphoma

摘要

Christian Recher and colleagues1 report thatintensifiedimmunochemotherapy with ACVBP plus rituximab (R-ACVBP) for patients with diffuse large B-cel! lymphoma improved outcomes compared with CHOP plus rituximab (R-CHOP). Although incidence of serious adverse events in the R-ACVBP group was higher than in the R-CHOP group (42% vs 15%), Recher and colleagues do not provide information to identify patients who might benefit from the intensified treatment.